Vutrisiran

4 trials 1 recruiting NNeurology/Psychiatry Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

1 Sponsors

20 Countries

Phase III

Phase III: 4

Indications tested

Cardiac amyloidosis 3 Polyneuropathy 1 Hereditary neuropathic amyloidosis 1

Sponsors using this IMP

Alnylam Pharmaceuticals Inc. 4

All trials

4 total

TRITON-PN: A Phase 3 Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin Amyloidosis with Poly… Recruiting

2025-522544-40-00 Phase III 9 countries Alnylam Pharmaceuticals Inc.
A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended

2024-518343-38-00 Phase III 11 countries Alnylam Pharmaceuticals Inc.
A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended

2024-518318-25-00 Phase III 16 countries Alnylam Pharmaceuticals Inc.
HELIOS-A: A Phase 3 Global Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis Ended

2023-508365-33-00 Phase III 7 countries Alnylam Pharmaceuticals Inc.

Showing 1–4 of 4 trials

← All drugs A–Z